Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: Efficacy and safety of Denosumab

Allan Lipton, Matthew R. Smith, Georgiana K. Ellis, Carsten Goessl

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.

Original languageEnglish (US)
Pages (from-to)287-303
Number of pages17
JournalClinical Medicine Insights: Oncology
Volume6
DOIs
StatePublished - Jan 1 2012

Fingerprint

Bone Fractures
Hormones
Safety
Neoplasms
Osteoclasts
Bone Density
Therapeutics
Prostatic Neoplasms
Breast Neoplasms
Bone and Bones
Aromatase Inhibitors
Bone Remodeling
Bone Resorption
Denosumab
Androgens
Osteoporosis
Estrogens
Monoclonal Antibodies
Placebos

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{a143f7ae23284f2b9bac1d6c149be534,
title = "Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: Efficacy and safety of Denosumab",
abstract = "Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.",
author = "Allan Lipton and Smith, {Matthew R.} and Ellis, {Georgiana K.} and Carsten Goessl",
year = "2012",
month = "1",
day = "1",
doi = "10.4137/CMO.S8511",
language = "English (US)",
volume = "6",
pages = "287--303",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy : Efficacy and safety of Denosumab. / Lipton, Allan; Smith, Matthew R.; Ellis, Georgiana K.; Goessl, Carsten.

In: Clinical Medicine Insights: Oncology, Vol. 6, 01.01.2012, p. 287-303.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy

T2 - Efficacy and safety of Denosumab

AU - Lipton, Allan

AU - Smith, Matthew R.

AU - Ellis, Georgiana K.

AU - Goessl, Carsten

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.

AB - Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.

UR - http://www.scopus.com/inward/record.url?scp=84866083139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866083139&partnerID=8YFLogxK

U2 - 10.4137/CMO.S8511

DO - 10.4137/CMO.S8511

M3 - Review article

C2 - 22933844

AN - SCOPUS:84866083139

VL - 6

SP - 287

EP - 303

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -